MetaLanc9 as a novel biomarker for non-small cell lung cancer: promising treatments via a PGK1-activated AKT/mTOR pathway

Ramon Andrade de Mello,Pedro Nazareth Aguiar,Hakaru Tadokoro, Tállita Meciany Farias-Vieira,Pedro Castelo-Branco,Gilberto Lopes,Daniel Humberto Pozza

JOURNAL OF THORACIC DISEASE（2018）

引用 12|浏览11

暂无评分

摘要

Non-small cell lung cancer (NSCLC) is still challenging in terms of screening and treatment approaches (1). In Europe, Latin-America and US, NSCLC is among the most common diseases for both men and women (2).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要